Navigation Links
Cenestra Health Announces Granting of Broad Patent Covering Proprietary Bioactive Lipid Formulations
Date:12/8/2011

NEW HAVEN, Conn., Dec. 8, 2011 /PRNewswire/ -- Cenestra Health announces that the U.S. Patent and Trademark Office (the "USPTO") has issued a new U.S. patent, No. 8,071,646 (the "'646 patent"), that protects and provides Cenestra with exclusivity for highly pure formulations of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in ratios ranging from about 3.5:1 to about 5:1.  The '646 patent provides exclusivity for these EPA:DHA ratios in compositions with > 84% omega-3s as the active ingredient. The '646 patent also provides exclusive rights to a number of uses for these superior EPA:DHA ratios.

While Cenestra's previously awarded U.S. patent No. 7,652,068 secured Cenestra's intellectual property on a composition of highly pure ethyl ester forms omega-3 formulations in EPA:DHA ratios of 4.1:1, the '646 patent greatly broadens the opportunity to develop highly unique and best in class EPA:DHA prescription products.  Both patents place Cenestra in a unique position to have therapeutically superior, patent protected products for treatment of diseases such as cardiovascular disease and depression.

"We are pleased that the USPTO recognized the novelty of these specific ratios of EPA to DHA that Cenestra discovered.  Cenestra's research shows that there are clearly superior ratios and dosages of these bioactive lipids for specified applications.  We hope to bring Cenestra's innovative products to patients afflicted with the illnesses that these specific ratios of omega-3s are optimized to treat," said Louis Sanfilippo, M.D., Assistant Clinical Professor at Yale School of Medicine and Managing Director of Cenestra Health.

"We believe that with the granting of the '646 patent, Cenestra finds itself in the unique position as the only high purity omega-3 company with straight-forward composition patents with long patent life remaining.  We believe this will allow Cenestra the ability to garner considerable investment in product development, and sales and marketing.  From the data Cenestra has generated to date, we expect the products developed under the Cenestra patents will confer superior efficacy to those currently on the market or announced to be in development," stated Dr. Sanfilippo. 

About Cenestra, LLC (D/B/A Cenestra Health)

Cenestra Health is a privately-held and unleveraged biopharmaceutical company based in New Haven, Connecticut. Cenestra Health was founded in 2005 to formulate, develop and market "best-in-class" proprietary natural products with applications in the OTC, medical food and pharmaceutical markets. Cenestra Health is focused on the clinical development of its late stage clinical drug candidates for the treatment of dyslipidemias and central nervous system disorders. Cenestra Health is planning to initiate Phase 3 registrational trials in early 2012.

About Omega-3 Essential Fatty Acids

Omega-3 fatty acids are considered "essential" fatty acids (EFAs) as they are necessary to human health but cannot be produced by the body. The two major health promoting omega-3 polyunsaturated fatty acids are eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). EPA and DHA have been shown to promote good physical and emotional health, reduce the risk of cardiovascular disease, and exert powerful anti-inflammatory effects. Omega-3 prescriptions in the United States alone accounted for over $1 billion dollars in sales in 2010.

Statements made in this press release should not to be construed as making any specific claim or claims in the diagnosis, prevention or treatment of any disease or disorder but  may relate to historical facts and information that reflect forward looking statements based on Cenestra Health's intellectual property and scientific data.    

  
Investor Contact:  Louis Sanfilippo, M.D., Managing Director
Email: investor.relations@cenestrahealth.com
Telephone: 203-362-8919
Website: www.cenestrahealth.com

US Patent No. 7,652,068/Omega-3 Fatty Acid Formulations
US Patent No. 8,071,646/Omega-3 Fatty Acid Formulations


'/>"/>
SOURCE Cenestra Health
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Cenestra Health Issued Notice of Allowance: Expands Patent Range of High-Purity Omega-3 Fatty Acid Formulations
2. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
3. SCAN Health Plan Offers Seniors Five Tips to Prepare for Surgery
4. Mergent, Inc. Announces Changes to the HealthShares(TM) European Drugs Index
5. Concentric Medical(R) Announces Co-Marketing Agreement With InTouch Health(R) to Advance Acute Ischemic Stroke Care
6. Mindray Medical to Attend Morgan Stanley Global Healthcare Unplugged Conference
7. BioNeutrals Ygiene(TM) New Hospital Grade Disinfectant Will Save Lives and Billions of Dollars Annually at Health Care Facilities Around the World
8. RF Technologies(R) Installs Safe Place(R) Solution for Pediatric and Infant Security at ProHealth Cares Waukesha Memorial Hospital
9. Rosetta Genomics and the National Institute of Health (NIH) to Identify Potential MicroRNA Drug Targets for HIV
10. Inc. Magazine Names Senior Whole Health the Number One Fastest-Growing Private Company in US
11. TVM Capital, Signet Healthcare Partners and Paul Capital Healthcare Enter into euro 26 Million Financing of SpePharm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , Feb. 5, 2016 Australian-US drug discovery and ... today the appointment of a new Chairman, Mr John ... , effective immediately. James Garner , has ... Director and former Acting CEO, Mr Iain Ross , ... Director. --> James Garner , has also been ...
(Date:2/4/2016)... ... February 04, 2016 , ... ... Club, takes place February 5-6 at the University’s student center, Kehr Union, ... such as workshops and competitions for ample networking, learning and collaborating opportunities. ...
(Date:2/4/2016)... N.J. , Feb. 4, 2016 ContraVir ... focused on the development and commercialization of targeted antiviral ... CEO & Investor Conference 2016, to be held February ... Source Capital Group,s 2016 Disruptive Growth & Healthcare Conference, ... on February 10-11, 2016. James Sapirstein , ...
(Date:2/4/2016)... Brooklyn, NY (PRWEB) , ... February 04, 2016 , ... ... cuvettes for over 10 years. What sets them apart from other cuvette ... that is posted on their website. On top of this steady flow of ...
Breaking Biology Technology:
(Date:1/25/2016)... SEATTLE , Jan. 25, 2016  Glencoe Software, ... biotech, pharma and publication industries, will provide the data ... Phenotypic Screening Centre (NPSC). ... Phenotypic analysis ... even whole organisms, allowing comparisons between states such as ...
(Date:1/22/2016)... 22, 2016 ... the "Global Biometrics Market in Retail ... --> http://www.researchandmarkets.com/research/p74whf/global_biometrics ) has ... Biometrics Market in Retail Sector 2016-2020" ... Research and Markets ( http://www.researchandmarkets.com/research/p74whf/global_biometrics ) ...
(Date:1/20/2016)... A market that just keeps on growing. Molecular Diagnostics ... genomics knowledge. Learn all about it in this new ... trends are pushing market growth and company valuations. Trends ... pathogen evolution - next generation sequencing - emergence of ... the role of genetic material in Disease and Health ...
Breaking Biology News(10 mins):